Integrating immunotherapy with radiotherapy to improve tumor control for canine cancer patients

Patient Disease:

Canine Neoplasia

Study Name:

Integrating immunotherapy with radiotherapy to improve tumor control for canine cancer patients

Purpose of the study:

  • To determine the effects of treating canine cancer patients with a combination of stereotactic body radiation therapy (SBRT) with either an injectable immunotherapy or vehicle control 

Primary Eligibility Criteria:

  • Dogs with peripheral tumors amenable for treatment with SBRT, local tumor injection, and tissue sampling via biopsy; no mast cell tumors or tumors affecting bone 

  • Good function of liver and kidneys, acceptable blood cell counts, and free of severe underlying disease

  • One week washout from chemotherapy, two weeks from immunotherapy; 3 month washout from radiation therapy to tumor 

Study Protocol:

  • Once enrolled, dogs will have blood samples collected for study purposes and then will be anesthetized for a CT scan for radiation planning; while under anesthesia, a small piece of tumor will be collected for the study 

  • Dogs will then return to start SBRT, which will be given in 3-5 treatments every day or every other day (depending on tumor type and location)

  • At the time of the last radiation treatment, the tumor will be injected with either the immunotherapy drugs or a placebo

  • Dogs will then return two weeks after completing radiation for blood work (complete blood count and chemistry profile), study blood collection, and sedation for tumor biopsy 

Owner Responsibilities:

  • Follow appointment schedule required by study protocol

  • Payment of the remainder of the costs for SBRT to treat the tumor (CT scan for SBRT treatment planning, SBRT), medications, any other tests recommended, as well as in the case of adverse events unrelated to the study 

Financial Incentives:

  • A $2,500 credit will be given to supplement treatment costs as incentive to participate in this study

  • The study will cover the costs of the additional diagnostic tests or sampling that are associated with this trial (blood work, study blood collections, and tumor biopsies)

  • In the case of adverse events directly related to this trial, up to $2,000 will be provided to supplement the costs of supportive care 


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.